Posted by Michael Wonder on 26 Apr 2023
Akebia receives European Commission approval for Vafseo (vadadustat) for the treatment of symptomatic anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis
25 April 2023 - -- Akebia Therapeutics today announced that the European Commission has granted marketing authorisation for Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
The approval is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein.
